The abstract is read at the publisher; the summary is JClub's.
Single-dose AGT-targeting GalNAc-siRNA (ART101) was well tolerated and produced mean maximum serum AGT reductions of 93% in healthy volunteers at 600 mg.
- Why it matters: Because hepatic angiotensinogen drives renin-angiotensin-aldosterone activity, a durable, long-acting suppression strategy could offer a new hypertension treatment approach.
- What they did: In a phase I trial in Beijing, 40 healthy adults received single subcutaneous doses (25–600 mg) or placebo in a double-blind part A, and 8 hypertension patients received 600 mg in open-label part B. Safety, pharmacokinetics (Cmax, AUC), pharmacodynamics (serum AGT), and exploratory 24-hour ambulatory blood pressure were assessed through 24 weeks.
- The result: No serious adverse events, injection site reactions, or hyperkalemia were observed, and plasma exposure increased with dose; at 24 weeks, placebo-corrected 24-hour ambulatory systolic blood pressure fell by 12.9 mm Hg in healthy participants.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.